Rilapladib
| CAS No. | 412950-08-4 | Cat. No. | BCP31473 |
| Name | Rilapladib | ||
| Synonyms | SB-659032; SB659032; SB 659032; GTPL7376; GTPL-7376; GTPL 7376; | ||
| Formula | C40H38F5N3O3S | M. Wt | 735.8 |
| Description | Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | Phosphatase | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.